[go: up one dir, main page]

EP2296624A1 - Nouvelles émulsions pour la préparation de médicaments - Google Patents

Nouvelles émulsions pour la préparation de médicaments

Info

Publication number
EP2296624A1
EP2296624A1 EP09761683A EP09761683A EP2296624A1 EP 2296624 A1 EP2296624 A1 EP 2296624A1 EP 09761683 A EP09761683 A EP 09761683A EP 09761683 A EP09761683 A EP 09761683A EP 2296624 A1 EP2296624 A1 EP 2296624A1
Authority
EP
European Patent Office
Prior art keywords
amino
water
oil
salt
quinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09761683A
Other languages
German (de)
English (en)
Inventor
Regis Cartier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to EP09761683A priority Critical patent/EP2296624A1/fr
Publication of EP2296624A1 publication Critical patent/EP2296624A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Definitions

  • the invention relates to processes for the preparation of stable polymer-based emulsions and the emulsions obtainable by means of these processes and medicaments which can be prepared therefrom.
  • the invention relates to stable, polymer-based emulsions for pulmonary or nasal inhalation and the use of these drugs for the treatment of respiratory diseases, in particular for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
  • COPD chronic obstructive pulmonary disease
  • Emulsions are systems in which a divided liquid phase (oil or
  • Droplet diameter is usually present in the nanometer to micrometer range in a further liquid phase.
  • the two liquid phases are immiscible.
  • a W / O (water in oil) emulsion is a system in which the aqueous phase is finely dispersed in droplet form in an oil phase.
  • the high degree of fragmentation i.e., the very small droplets causes a very high surface area of the internal phase.
  • emulsions are thermodynamically stable and form a clear to opalescent, fluid system of oily consistency.
  • the special properties of the emulsions are closely related to their colloidal chemical structure, which is a consequence of the chemical composition and the production process of the emulsions.
  • emulsifiers for the preparation of emulsions so-called emulsifiers as
  • emulsifiers for the production of W / O (water in oil) emulsions consist chemically of a water-soluble and a lipophilic portion within the
  • the prior art mainly uses lipids and polymers.
  • the pharmaceutical performance of a drug containing an emulsion can thereby be improved by minimizing the hydrophilic portion of the emulsifier.
  • Under pharmaceutical performance are the physical properties, eg. B. stability, physicochemical properties, pharmacological properties, toxicological properties and pharmacokinetic properties. Among other things, these properties can be monitored by a high loading rate of the emulsion with an active ingredient, an improvement in a targeted release of an active ingredient over time, a reduction in toxicity or a delayed degradation of the formulation over time.
  • the emulsions can be used as a precursor for the production of solid particles, for example in the context of a spray-drying process.
  • the emulsion serves as a spray solution of the spray-drying process.
  • the emulsions are used as a precursor of solid drugs, it is advantageous if the emulsions are composed in such a way that the solid particles produced from the emulsion have a high glass transition temperature.
  • auxiliaries it is an object of the invention to provide stable emulsion with weak emulsifiers and methods for their preparation. It is also an object of the invention to provide stable emulsion with weak emulsifiers whose content of emulsifier is kept as low as possible. In addition, it is an object of the invention to provide medicaments containing emulsions according to the invention.
  • W / O (water in oil) emulsions according to the invention are further characterized in that the ionic strength of the aqueous phase used to prepare the emulsions of the invention has an ionic strength of greater than 10 mM (unit: milli-moles / liter). Preferred is an ionic strength of 15 mM, 20 mM, 30 mM and 50 mM.
  • aqueous phases having an ionic strength between 10 mM and 500 mM, between 15 mM and 500 mM, 20 mM and 500 mM, between 30 mM and 500 mM, between 10 mM and 400 mM, between 15 mM and 400 mM, between 20 mM and 400 mM, between 30 mM and 400 mM, between 10 mM and 300 mM, between 20 mM, 300 mM, between 30 mM and 300 mM, between 10 mM and 200 mM, between 20 mM, 200 mM, between 30 mM and 200 mM.
  • W / O (water in oil) emulsions according to the invention are further characterized in that emulsifiers from the group of co-polymers, in particular from the group of block co-polymers, are preferably used for their preparation.
  • emulsifiers from the group of co-polymers in particular from the group of block co-polymers, are preferably used for their preparation.
  • polymers from the substance class of PEG [poly (lactide-co-glycolides)] or the substance class of PEG [poly-lactides] are suitable as emulsifiers for the novel W / O (water in oil) emulsions, if these have the structure of block copolymers.
  • PEG stands for polyethylene glycol.
  • block copolymers polymers consisting of longer sequences or blocks of each monomer (e.g., aaaaaaaabbbbbbbbbbb ).
  • a diblock structure or triblock structure is to be understood as meaning that the polymer is composed of different units which are repeated regularly at the molecular level.
  • the emulsifiers can be selected from the class of block co-polymers. These contain at least one water-soluble block (block B) and at least one non-water-soluble block (block A).
  • blocks B water-soluble block
  • block A non-water-soluble block
  • compounds which have a diblock structure (AB) or a triblock structure (ABA) can be used as block co-polymers, block A consisting of successive monomer units aaaaaaaa... Of a first polymer and block B of successive monomer units bbbbbbbbb ... of the second polymer.
  • water-soluble block B PEG (polyethylene glycol) is used to a particular degree.
  • non-water-soluble block A a polyester compound is chosen in particular.
  • the polymer class of the poly (lactide-co-glycolides) or the polymer class of the poly-lactides is used as the polyester block.
  • emulsifiers selected from the class PEG- [poly (lactide-co-glycolides)] or the class of PEG- [poly-lactides].
  • PEG- poly (lactide-co-glycolides)
  • PEG- poly-lactides
  • Such substances are available under the name Resomer® (Boehringer Ingelheim Pharma GmbH & Co. KG, Germany).
  • polymers of these two classes of substances are suitable if they have the following properties (a), (b), (c), (d) and (e):
  • a lactide content of 50-100% (mass% based on molecular mass and 100% based on the molecular mass of polymer block A of the block co-polymer) and thereby the lactide content of the components L-lactide and may contain D-lactide and the D-lactide to the L-lactide is present in the ratio n ⁇ at most and n is a number less than or equal to 1, optionally the lactide portion consists exclusively of L-lactide.
  • substances from the class of PEG- [poly (lactide-co-glycolide)] 5 block co-polymers are suitable if they have the following properties (a), (b), (c), (d) and (e) include:
  • a lactide content of 50-99% (mass% based on molecular mass 15 and 100% based on the molecular mass of the polymer block A of the block co-polymer) and thereby the lactide content of the components L- Lactide and D-lactide may contain and the D-lactide to L-lactide maximally in the ratio n: ⁇ is present and n is a number less than or equal to 1, where appropriate, the lactide portion consists exclusively of L-lactide.
  • substances from the class of PEG [poly-lactide] block co-polymers are suitable if they have the following properties (a), (b), (c), and (f):
  • lactide portion may contain the components L-lactide and D-lactide and the D-lactide to L-lactide maximum in the ratio n ⁇ is present and n is a number less than or equal to 1, optionally the lactide portion exclusively made of L-lactide.
  • the emulsifiers are preferably used according to the invention in a concentration of 0.5%, 0.75%, 1%, 1.25% and 1.5%, preferably 0.75% used (mass% of the emulsifier based on the mass of the oil phase).
  • the emulsifiers for the production of W / O (water in oil) - emulsions in a concentration of 0.5% to 20%, 0.5% to 10%, 0.5% to 5%, preferably 0.5% to 2%, more preferably 0.75% to 1% are used (mass% of the emulsifier based on the mass of the oil phase).
  • the W / O (water in oil) emulsions in a specific embodiment are characterized in that the emulsion droplets have a hydrodynamic diameter between 200 nm and 3000 nm, preferably, 300 nm and 3000 nm, preferably, 300 nm and 2500 nm 500 nm and 2500 nm, preferably 500 nm and 2100 nm.
  • the hydrodynamic diameter is understood to mean the mean equivalent diameter, as can be determined by means of photon correlation spectroscopy (more details in the Experimental Section).
  • the invention relates to processes for the production of novel W / O (water in oil) emulsions, by means of which the objects according to the invention are achieved.
  • the preparation of W / O (water in oil) emulsions according to the invention can be carried out, for example, by adding an alkali metal salt, an alkaline earth metal salt, an acid addition salt of an active compound or a combination thereof before the preparation of the emulsion.
  • an acid addition salt of an active ingredient this acid addition salt is present in the aqueous phase in dissociated form.
  • the preparation of such a W / O (water in oil) emulsion comprises a process step characterized in that a salt is dissolved in the aqueous phase used to prepare the W / O (water in oil) emulsion ,
  • This salt may be an inorganic salt or an organic salt, for example the acid addition salt of an active ingredient.
  • the alkali metal salts and alkaline earth metal salts may be mentioned, wherein the anion may be selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate , Succinate, benzoate and p-toluenesulfonate.
  • the anion may be a single negatively charged anion selected from the group consisting of Fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide and chloride.
  • the cation may, for example, be selected from lithium, sodium, potassium, beryllium, magnesium, calcium, strontium and barium. Of particular importance are sodium, potassium, magnesium and calcium.
  • the process for producing W / O (water-in-oil) emulsions according to the invention comprises a process step which is characterized in that an organic phase contains an emulsifier from the substance class of PEG [poly (lactide-co-glycolides). ] or the PEG [poly-lactides] is added.
  • This organic phase is then processed in a further step together with an aqueous phase in which a salt is dissolved by intensive mixing to form a W / O (water in 01) emulsion.
  • This salt may be an inorganic salt or an organic salt, for example the acid addition salt of an active ingredient. Examples of possible salts are the alkali metal salts and alkaline earth metal salts, preferably sodium chloride.
  • the salts are considered equivalent to the use of active ingredients which, due to their ionic structure, have an ionic strength of more than 10 mM, also preferably 15 mM, 20 mM, 30 mM and 50 mM.
  • the emulsion is obtainable by homogenizing the organic and aqueous phases by intensive mixing.
  • the mixing process can also be carried out in an ultrasonic bath or an ultrasonic finger while ultrasound is applied to the mixture at the same time.
  • the invention relates to the use of W / O (water in oil) emulsions for the production of dry powder formulations for medicaments to be administered by inhalation.
  • the invention also relates to the use of the emulsions according to the invention as a spray solution for spray drying.
  • the spray-drying of pure active ingredients for inhalation purposes has been described in the prior art [for example: EP 0 072 046 A1; WO 2000 000176 A1; US 6019968; A. Chawla, K.M.G. Taylor, J.M. Newton, M.C.R. Johnson, Int. J. Pharm, 108 (3), (1994), 233-240].
  • the W / O (water in oil) emulsions according to the invention can be used for the preparation of a medicament. Preference is given to the production of a medicament for the treatment of respiratory diseases, in particular for the treatment of COPD and / or asthma.
  • the invention relates to the use the thus obtained W / O (water in oil) emulsions for the manufacture of a medicament for inhalation use in particular measure for the manufacture of a medicament for inhalation use, which allows a delayed release of the active ingredient.
  • W pharmacologically active agents
  • W Anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HIV antihistamines, PAF antagonists and PI3 kinase inhibitors.
  • two- or three-fold combinations of W can be combined and used for application in the device according to the invention. Exemplary combinations of W would be:
  • W represents a betamimetics combined with an anticholinergic, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists
  • W represents an anticholinergics combined with a betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists
  • W represents a corticosteroid combined with a PDE4 inhibitor, EGFR
  • W represents a PDE4 inhibitor combined with an EGFR inhibitor or LTD4
  • W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Preferred betamimetics for this purpose are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharines, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol , Orciprenaline, Pirbuterol, Procaterol, Reproterol, Rimiterol, Ritodrine, Salmefamol, Salmeterol, Soterenol, Sulphone terol, Terbutaline, Tiaramide, Tolubuterol, Zinterol, CHF-1035, HOKU-81, KUL-1248 and
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro- toluenesulfonate.
  • anticholinergic compounds are preferably used here, which are selected from the group consisting of tiotropium salts, preferably the
  • the cations are the pharmacologically active ingredients.
  • the aforementioned salts may preferably contain chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate , Benzoate or p-toluenesulfonate, where chloride, bromide, Iodide, sulfate, methanesulfonate or p-toluenesulfonate are preferred as counterions.
  • the chlorides, bromides, iodides and methanesulfonates are particularly preferred.
  • anticholinergics are selected from the salts of the formula AC-I
  • X ⁇ is a single negatively charged anion, preferably an anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, lo nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulfonate, preferably a singly negatively charged anion, more preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide, optionally in the form of their racemates, enantiomers or hydrates , Of particular importance are those
  • X ⁇ can have the meanings given above.
  • 20 preferred anticholinergics are selected from the salts of the formula AC-2
  • R is either methyl or ethyl and in which X may have the abovementioned meanings.
  • the compound of the formula AC-2 may also be present in the form of the free base AC-2-base.
  • Preferred corticosteroids are compounds selected from the group consisting of beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR - 106541, NS-126, ST-26 and - 6,9-difluoro-17 - [(2-furanylcarbonyl) oxy] -1-hydroxy-16-methyl-3-oxo-androsta-1, 4-diene 17-carbothionic acid (S) -fluoromethyl ester
  • Examples of possible salts and derivatives of steroids may be: alkali metal salts, such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • alkali metal salts such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • Preferred PDE4 inhibitors here are compounds which are selected from the group consisting of enprofylline, theophylline, roflumilast,
  • the acid addition salts of the PDE4 inhibitors are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate,
  • Hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate are Hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred LTD4 antagonists here are compounds selected from the group consisting of montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078 , VUF-K-8707, L-733321 and
  • alkali metal salts such as, for example, sodium or potassium salts, alkaline earth salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
  • the EGFR inhibitors used are preferably compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and - 4 - [(3-chloro-4-fluorophenyl) amino] -6- ⁇ [4- (morpholin-4-yl) -1-oxo-2-buten-1-yl] amino ⁇ -7-cyclopropylmethoxyquinazoline
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred dopamine agonists are compounds selected from the group consisting of bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole, roxindole, ropinirole, talipexole, terguride and viozan, optionally in the form of their racemates, enantiomers , Diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Hl antihistamines here preferably compounds are used, which are selected from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, Cexchlorpheniramin, pheniramine, doxylamine, chlorphenoxamine , Dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclocine, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • substance formulations or substance mixtures all inhalable compounds are used, such as, for example, inhalable macromolecules, as disclosed in EP 1 003 478.
  • substances, substance formulations or substance mixtures are used for the treatment of respiratory diseases, which are used in the inhalation area.
  • the compound may be derived from the group of derivatives of ergot alkaloids, triptans, CGRP inhibitors, phosphodiesterase V inhibitors, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmacologically acceptable acid addition salts, their solvates and / or or hydrates.
  • the meter calculates the hydrodynamic diameter (Dh) of a suspension and gives the size distribution (volume-related determination mode).
  • the measurement results listed below correspond to the respective main peaks of the determined size distributions (for the purposes of this invention, the droplet size of the main peak corresponds to the hydrodynamic diameter).
  • the preparation of the emulsion solutions in the following Examples 1 to 4 was carried out such that the active ingredients or polymers were dissolved in a concentration of 0.75% (weight per volume in grams per 100 milli liters) in their respective phase.
  • the phases were combined and treated by means of an ultrasonic finger for 2 min at 30% power.
  • the tip is immersed 0.5 - 2 cm in the solution and the ultrasonic apparatus (manufacturer: Sonics & Materials Inc. (Darbury, CT, USA), type: "Vibra Cell", model: VC 50) at 30% of the maximum force Operated for 5 minutes. Influence of the ionic strength on the stability of the W / O (water in Q1) emulsions according to the invention
  • Example 1 Stability of W / O (water in oil) emulsions with different salts as a function of time
  • FIG. 1 shows W / O (water-in-oil) emulsions according to the invention which contain, as emulsifier, the polymer of the Resomer® type LGPt8546 (see legend of the figure and details according to Table 1).
  • DCM dichloromethane
  • the organic phase was then processed with an aqueous phase in a ratio of 1: 4 (volume: volume, i.e. one volume of aqueous phase to four volumes of organic phase) to form an emulsion by sonication.
  • the respective aqueous phase contained a different salt in an ionic strength of 20 mM.
  • the emulsions obtained are thus (W / O) water-in-oil emulsions (water / DCM emulsions).
  • Example 3 Stability of W / O (water in oil) Emulsion with different emulsifiers (polymers) as a function of time
  • the W / O (water-in-oil) emulsions according to the invention of the results shown in Figure 3 were obtained by dissolving as emulsifiers various Resomer® type polymers (in the organic phase (DCM)) in the inorganic (aqueous) phase Salbutamol sulphate salt was dissolved from these phases W / O 5 (water / DCM) emulsions, the amount of aqueous phase to the organic phase being 1: 4 (volume: volume, ie one volume of aqueous phase to four volumes of organic phase), produced by ultrasonic treatment.
  • DCM organic phase
  • Salbutamol sulphate salt was dissolved from these phases W / O 5 (water / DCM) emulsions, the amount of aqueous phase to the organic phase being 1: 4 (volume: volume, ie one volume of aqueous phase to four volumes of organic phase), produced by ultrasonic treatment.
  • all W / O (water / DCM) -10 emulsions according to the invention exhibit stable behavior.
  • the emulsion droplet size (hydrodynamic diameter of the emulsion) is in a suitable range between 300 nm and 3000 nm.
  • the emulsion droplet size remains stable at least within the measurement period of about 1 hour within this range suitable for the droplet size.
  • FIG. 4 Further examples of the stability behavior of W / O (water-in-oil) emulsions according to the invention are shown in Figure 4 (x-axis: measurement time of determining the hydrodynamic diameter, the zero value indicating the time of preparation of the emulsion, y-axis: hydrodynamic Diameter ie).
  • the W / O (water in oil) emulsions of the invention shown in FIG. 4 can be obtained in a comparable manner to Examples 1 to 3.
  • the composition was chosen such that
  • the emulsifier used was LGPt8546 (see legend of the figure and data according to Table 1).
  • all W / O (water / DCM) emulsions according to the invention exhibit stable behavior.
  • the emulsion droplet size (hydrodynamic oil diameter of the emulsion) is in a suitable range between 300 nm and 3000 nm.
  • the emulsion droplet size remains stable at least within the measurement period of about 1 hour within this range suitable for the droplet size.
  • Table 2 Composition of the emulsions prepared according to Examples 1 to 4 (% data corresponds to mass per volume (w / v) in grams per 100 milli liters).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Colloid Chemistry (AREA)

Abstract

L'invention porte sur l'obtention d'émulsions stables à base de polymère, lesquelles présentent une force ionique supérieure à 10 mM dans leur phase aqueuse, ainsi que sur un procédé de préparation de ces émulsions, et sur des médicaments obtenus à l'aide desdites émulsions.
EP09761683A 2008-06-09 2009-06-08 Nouvelles émulsions pour la préparation de médicaments Withdrawn EP2296624A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09761683A EP2296624A1 (fr) 2008-06-09 2009-06-08 Nouvelles émulsions pour la préparation de médicaments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08104313 2008-06-09
EP09761683A EP2296624A1 (fr) 2008-06-09 2009-06-08 Nouvelles émulsions pour la préparation de médicaments
PCT/EP2009/057009 WO2009150120A1 (fr) 2008-06-09 2009-06-08 Nouvelles émulsions pour la préparation de médicaments

Publications (1)

Publication Number Publication Date
EP2296624A1 true EP2296624A1 (fr) 2011-03-23

Family

ID=40010770

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09761683A Withdrawn EP2296624A1 (fr) 2008-06-09 2009-06-08 Nouvelles émulsions pour la préparation de médicaments

Country Status (5)

Country Link
US (1) US20110200643A1 (fr)
EP (1) EP2296624A1 (fr)
JP (1) JP2011525177A (fr)
CA (1) CA2727297A1 (fr)
WO (1) WO2009150120A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL430675A1 (pl) * 2019-07-23 2021-01-25 Osęka Maciej Bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) oraz kompozycja farmaceutyczna zawierająca bromokryptynę

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
DE19813174A1 (de) * 1998-03-25 1999-05-27 Schering Ag Mikropartikel aus Polymeren und mindestens einer gerüstbildenden Komponente und ihre Herstellung und Verwendung in der Ultraschalldiagnostik und zur ultraschallinduzierten Wirkstofffreisetzung
AU2001281288A1 (en) * 2000-07-18 2002-01-30 Aeropharm Technology Incorporated Modulated release therapeutic aerosols
DE10355711A1 (de) * 2003-11-26 2005-06-16 Beiersdorf Ag Kosmetische und dermatologische Emulsionen, enthaltend Kreatin und/oder Kreatinin und Elektrolytkonzentrationen, einer Ionenstärke von mindestens 50 mmol/l
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
EP2074989B1 (fr) * 2004-02-23 2013-11-20 Euro-Celtique S.A. Dispositif d'administration transdermique opioïde résistante aux abus
US20060147520A1 (en) * 2004-07-26 2006-07-06 Curtis Ruegg Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009150120A1 *

Also Published As

Publication number Publication date
WO2009150120A1 (fr) 2009-12-17
US20110200643A1 (en) 2011-08-18
CA2727297A1 (fr) 2009-12-17
JP2011525177A (ja) 2011-09-15

Similar Documents

Publication Publication Date Title
EP2007349B1 (fr) Formulations de suspensions pour aérosols utilisant du tg 227 ea ou du tg 134 a comme propulseur
EP2004263B1 (fr) Dispositif d'émission de médicaments et magasins à médicaments
EP1948274B1 (fr) Aiguille pour percer des capsules de poudre pour l'inhalation
EP2254630A1 (fr) Inhalateurs de poudre
EP2370053A1 (fr) Nouveaux médicaments sous forme de poudre cristalline à inhaler
EP2066380A2 (fr) Inhalateur
EP2001601B1 (fr) Aérosols de dosage pour l'administration de préparations pharmaceutiques
EP2299990A1 (fr) Nouvelles particules à principe actif incorporé pour inhalation
WO2007048763A1 (fr) Inhalateur avec embout ayant une fonction de protection microbiologique
EP2170730A1 (fr) Nouvel agent pharmaceutique poudreux contenant du tiotropium et du salmétérol ainsi que du lactose en tant qu'agent auxiliaire
EP2296624A1 (fr) Nouvelles émulsions pour la préparation de médicaments
WO2007023167A1 (fr) Systeme transcorneen permettant de delivrer une substance active medicamenteuse
DE102006044755A1 (de) Inhalator
EP2244686A1 (fr) Procédé et dispositif pour remplir des gélules
WO2006037736A1 (fr) Poudres a inhaler a base de melanges de lactoses modifies comme auxiliaires
DE102005059602A1 (de) Verfahren zur Mikronisierung
WO2007048764A2 (fr) Absorption du gaz propulseur d'aerosols-doseurs pourvus d'emballages
EP2001536A1 (fr) Emballage pour inhalateur de poudre multidose avec proprietes optimisees de purge
WO2006037738A1 (fr) Modification de surfaces de lactose utilise comme auxiliaire, pour des agents d'inhalation pulverulents
DE102007052871A1 (de) Kapsel zur Aufnahme von pharmazeutischen Wirkstoffformulierungen
DE102007036413A1 (de) Vorrichtung und Verfahren zur Bestimmung des Feuchtegehalts eines Verpackungsmaterials

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

17Q First examination report despatched

Effective date: 20110714

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140103